154 related articles for article (PubMed ID: 16339756)
1. TP53 mutation and microsatellite instability status for the prediction of survival in adjuvant-treated colon cancer patients.
Watanabe T; Kanazawa T; Kazama Y; Tanaka J; Tanaka T; Ishihara S; Nagawa H
J Clin Oncol; 2005 Dec; 23(35):9031-2; author reply 9032-3. PubMed ID: 16339756
[No Abstract] [Full Text] [Related]
2. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
3. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability in colon cancer.
Allegra CJ; Kim G; Kirsch IR
N Engl J Med; 2003 Oct; 349(18):1774-6; author reply 1774-6. PubMed ID: 14585950
[No Abstract] [Full Text] [Related]
5. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.
Elsaleh H; Powell B; Soontrapornchai P; Joseph D; Goria F; Spry N; Iacopetta B
Oncology; 2000; 58(1):52-9. PubMed ID: 10644941
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age.
Liang JT; Huang KC; Cheng AL; Jeng YM; Wu MS; Wang SM
Br J Surg; 2003 Feb; 90(2):205-14. PubMed ID: 12555297
[TBL] [Abstract][Full Text] [Related]
7. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer.
Kumar S; Chang EY; Frankhouse J; Dorsey PB; Lee RG; Johnson N
Arch Surg; 2009 Sep; 144(9):835-40. PubMed ID: 19797108
[TBL] [Abstract][Full Text] [Related]
8. Two colons-two cancers: paradigm shift and clinical implications.
Gervaz P; Bucher P; Morel P
J Surg Oncol; 2004 Dec; 88(4):261-6. PubMed ID: 15565587
[TBL] [Abstract][Full Text] [Related]
9. A substantial proportion of microsatellite-unstable colon tumors carry TP53 mutations while not showing chromosomal instability.
Westra JL; Boven LG; van der Vlies P; Faber H; Sikkema B; Schaapveld M; Dijkhuizen T; Hollema H; Buys CH; Plukker JT; Kok K; Hofstra RM
Genes Chromosomes Cancer; 2005 Jun; 43(2):194-201. PubMed ID: 15729700
[TBL] [Abstract][Full Text] [Related]
10. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Ribic CM; Sargent DJ; Moore MJ; Thibodeau SN; French AJ; Goldberg RM; Hamilton SR; Laurent-Puig P; Gryfe R; Shepherd LE; Tu D; Redston M; Gallinger S
N Engl J Med; 2003 Jul; 349(3):247-57. PubMed ID: 12867608
[TBL] [Abstract][Full Text] [Related]
11. Response to 5-fluorouracil of orthotopically xenografted human colon cancers with a microsatellite instability: influence of P53 status.
Pocard M; Bras-Gonçalves R; Hamelin R; Northover J; Poupon MF
Anticancer Res; 2000; 20(1A):85-90. PubMed ID: 10769638
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
Kornmann M; Formentini A; Ette C; Henne-Bruns D; Kron M; Sander S; Baumann W; Kreuser ED; Staib L; Link KH
Eur J Surg Oncol; 2008 Dec; 34(12):1316-21. PubMed ID: 18313881
[TBL] [Abstract][Full Text] [Related]
14. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal.
Köhne CH
Lancet Oncol; 2006 Jun; 7(6):516-7. PubMed ID: 16767832
[No Abstract] [Full Text] [Related]
15. Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Iacopetta B; Watanabe T
Gut; 2006 Nov; 55(11):1671-2. PubMed ID: 17047121
[No Abstract] [Full Text] [Related]
16. Thymidylate synthase expression in colon carcinomas with microsatellite instability.
Sinicrope FA; Rego RL; Halling KC; Foster NR; Sargent DJ; La Plant B; French AJ; Allegra CJ; Laurie JA; Goldberg RM; Witzig TE; Thibodeau SN
Clin Cancer Res; 2006 May; 12(9):2738-44. PubMed ID: 16675565
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy for colon cancer--the pace quickens.
Allegra C; Sargent DJ
N Engl J Med; 2005 Jun; 352(26):2746-8. PubMed ID: 15987925
[No Abstract] [Full Text] [Related]
19. Progress and challenges in the adjuvant treatment of stage II and III colon cancers.
Chua YJ; Zalcberg JR
Expert Rev Anticancer Ther; 2008 Apr; 8(4):595-604. PubMed ID: 18402526
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy of colon cancer: current status and future directions.
Chung KY; Saltz LB
Cancer J; 2007; 13(3):192-7. PubMed ID: 17620769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
